Floatz logo

arx788

Hormone Receptor Negative Tumor

QuantumLeap Healthcare CollaborativePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

71 Active assets in the Hormone Receptor Negative Tumor cohort.

Asset / SponsorPhaseRating
Rivoceranib
Fudan University
Phase 2CCC
tqb2868
Fudan University
Phase 2CCC
Rilvegostomig
QuantumLeap Healthcare Collaborative
Phase 2CCC
Sarilumab
QuantumLeap Healthcare Collaborative
Phase 2CCC
Irinotecan
QuantumLeap Healthcare Collaborative
Phase 2CCC

View all 50 →

Same molecule, other indications

arx788 is also rated in:

neoplasmDormant
B
Indicative ·
60 / 100
View asset →
HER2 positive breast carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
HER2 Amplified Solid TumorsDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →